ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Rochester, MN, USA:

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Rochester, Minnesota, United States and 88 other locations

administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...

Enrolling
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: CFT7455

Phase 1, Phase 2

C4 Therapeutics

Rochester, Minnesota, United States and 12 other locations

patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...

Active, not recruiting
Non-Hodgkin's Lymphoma
Small Lymphocytic Lymphoma
Drug: CG-806

Phase 1

Aptose Biosciences

Rochester, Minnesota, United States and 29 other locations

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non...

Enrolling
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Drug: DTRM-555

Phase 2

Zhejiang DTRM Biopharma

Rochester, Minnesota, United States and 7 other locations

according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in eac-...

Enrolling
B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Rochester, Minnesota, United States and 137 other locations

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during...

Enrolling
Marginal Zone Lymphoma
Follicular Lymphoma
Biological: rituximab
Biological: EO2463

Phase 1, Phase 2

Enterome

Rochester, Minnesota, United States and 9 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Rochester, Minnesota, United States and 125 other locations

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Rituximab

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Rochester, Minnesota, United States and 55 other locations

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and...

Enrolling
Peripheral T Cell Lymphoma
FL Lymphoma
Drug: HH2853 Tablets

Phase 1, Phase 2

Haihe Biopharma

Rochester, Minnesota, United States and 24 other locations

Locations recently updated

safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

Phase 2

Genentech
Genentech

Rochester, Minnesota, United States and 57 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems